Is it time for flexibility in botulinum inter-injection intervals?

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Toxicon

• Publication date

  2015-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.toxicon.2015.09.037PMID 26440738
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians)

  2014influential reference
• Biophysical characterization.

  2014cited by this paper
• Botulinum Toxin Therapy for Cervical Dystonia: The Science of Dosing

  2014cited by this paper
• IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.

  2014cited by this paper
• Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm

  2013cited by this paper
• Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®)

  2013cited by this paper
• Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia

  2013cited by this paper
• Incobotulinumtoxin A (Xeomin®) injected with flexible intervals is a well-tolerated long-term treatment of cervical dystonia

  2013cited by this paper
• Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia

  2012cited by this paper
• Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm—A randomized trial

  2011cited by this paper
• EFNS guidelines on diagnosis and treatment of primary dystonias

  2011cited by this paper
• Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications

  2010cited by this paper
• Neutralizing Antibodies and Secondary Therapy Failure After Treatment With Botulinum Toxin Type A: Much Ado About Nothing?

  2009cited by this paper
• Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

  2008cited by this paper
• Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

  2008cited by this paper
• Dissociation of the 900 kDa neurotoxin complex from C. botulinum under physiological conditions

  2008cited by this paper
• Botulinum toxin treatment of axial and cervical dystonia

  2007cited by this paper
• A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS‐ES Task Force

  2006cited by this paper
• EFFICACY AND SAFETY OF

  2004cited by this paper
• Development of resistance to botulinum toxin type A in patients with torticollis

  2004cited by this paper
• Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia

  2003cited by this paper
• A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.

  2001cited by this paper
• Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review.

  2000cited by this paper
• Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.

  1999cited by this paper
• Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency

  1999cited by this paper
• Biophysical Characterization of the Stability of the 150-Kilodalton Botulinum Toxin, the Nontoxic Component, and the 900-Kilodalton Botulinum Toxin Complex Species

  1998cited by this paper
• Botulinum toxin therapy, immunologic resistance, and problems with available materials

  1996cited by this paper
• Response and immunoresistance to botulinum toxin injections

  1995cited by this paper
• Botulinum antibodies in dystonic patients treated with type A botulinum toxin

  1993cited by this paper
• Oral toxicities of Clostridium botulinum toxins in response to molecular size

  1977cited by this paper
• Neurology and Preclinical Neurological Studies -original Article

  year unknowncited by this paper

• New trends in the treatment of blepharospasm: replacing the standardized approach with a personalized approach

  2025cites this paper
• Development of a Patient-Centered Outcome Tool for Blepharospasm: A Stepwise Modified Delphi Study

  2025cites this paper
• A digital patient-centered outcome tool for cervical dystonia

  2024cites this paper
• Botulinum Toxin for the Treatment of Raynaud’s Conditions of the Hand: Clinical Practice Updates and Future Directions

  2024cites this paper
• Long‐pulsed Nd: YAG laser (1064 nm) versus intralesional botulinum toxin type (A) in acne vulgaris therapy: a split face study

  2022cites this paper
• Anomalies of motor unit amplitude and territory after botulinum toxin injection

  2022cites this paper
• Perspectives on the pharmacological management of dystonia

  2021cites this paper
• Nonlinear Changes in Botulinum Toxin Treatment of Task-Specific Dystonia during Long-Term Treatment

  2021cites this paper
• Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies

  2020cites this paper
• Medical and Surgical Treatments for Dystonia.

  2020cites this paper
• Subcutaneous botulinum toxin type A injections for provoked vestibulodynia: a randomized placebo-controlled trial and exploratory subanalysis

  2019cites this paper
• The Dystonias.

  2019cites this paper
• The Dystonias.

  2019cites this paper
• Immunogenicity Associated with Botulinum Toxin Treatment

  2019cites this paper
• Mitos y evidencias en el empleo de la toxina botulínica: neurofarmacología y distonías

  2018cites this paper
• Treatment of Blepharospasm/Hemifacial Spasm

  2017cites this paper
• Botulinumtoxin-Therapie bei Dystonien

  2017cites this paper
• Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia

  2017cites this paper
• Do flexible inter-injection intervals improve the effects of botulinum toxin A treatment in reducing impairment and disability in patients with spasticity?

  2017cites this paper